Combination Targeted Radiotherapy in Neuroendocrine Tumors

NACompletedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

September 30, 2006

Primary Completion Date

April 30, 2008

Study Completion Date

July 31, 2015

Conditions
Neuroendocrine Tumors
Interventions
OTHER

131-I MIBG and 111-In pentetreotide

Subjects will receive 131I MIBG and 111In pentetreotide(surrogate for Y90-DOTATOC)

OTHER

131-I MIBG and In-111 DOTATATE

131I MIBG and In-111 DOTATATE (surrogate for 177Lu DOTATATE)

Trial Locations (2)

52242

University of Iowa, Iowa City

52246

Department of Veteran Affairs Medical Center, Iowa City

All Listed Sponsors
collaborator

VA Office of Research and Development

FED

lead

David Bushnell

OTHER

NCT01099228 - Combination Targeted Radiotherapy in Neuroendocrine Tumors | Biotech Hunter | Biotech Hunter